Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India

Bhagwat Gunale ,Melinda Pryor,Stephanie Hamilton,Chetanraj Bhamare ,Sunil Kohli ,Kamlesh Mahajan ,H V Prajwala ,Chetna A Shyamkuwar ,Mingzhu Zhu ,Alok Arya ,Payal Meshram ,Vijayshri Deotale ,Shane Cloney-Clark ,Anand Kawade ,Vineet Jain ,Temsunaro Rongsen-Chandola ,Madhuri Thakar ,Gregory M Glenn ,Arunkumar Gondhali ,Joyce S Plested ,Sonali Palkar ,Praveen Kulkarni ,Indira Sharma ,Rahul Choche ,Ashish Bavdekar ,Ashwini Shete ,Sonali Kar ,Sushant Meshram ,Dhananjay Kapse ,Aradhana Singh ,Nusrat Shafiq ,Pramod C Samantaray ,Renuka Munshi ,Umesh Shaligram ,Nidhi Goyal ,M Bhatnagar ,Prasad S Kulkarni ,Madhu Gupta ,Deepak Ghatage ,Cyrus S Poonawalla ,Ashwini Kalantri ,Abhishek Raut ,Abhijeet Dharmadhikari ,Neeta Hanumante ,B S Garg ,Sanjay Lalwani ,Dipti Kumbhar ,Raburn M Mallory ,Clarence Samuel ,Vivek Rao ,Deepshikha Kamra ,Sugam Salvi

doi:10.1001/jamapediatrics.2023.2552

Abstract

The recombinant COVID-19 vaccine NVX-CoV2373 has demonstrated efficacy of approximately 90% in adults; however, its safety and efficacy in children is unknown. To assess the noninferiority of SII-NVX-CoV2373 in children and adolescents compared to adults and to evaluate its safety in comparison with placebo. This phase 2-3 observer-blind randomized clinical trial was conducted in 2 cohorts, children (aged 2 to 11 years) and adolescents (aged 12 to 17 years) between August 2021 and August 2022. Participants were randomized 3:1 to SII-NVX-CoV2373 or placebo and monitored for 179 days. The participants, study team, and laboratory staff were blinded. This was a multicenter study conducted across 10 tertiary care hospitals in India. Exclusion criteria included previous COVID-19 infection or vaccination, immunocompromised condition, and immunosuppressive medications. Two doses of 0.5-mL SII-NVX-CoV2373 or placebo were administered intramuscularly on days 1 and 22. Primary outcomes were geometric mean titer ratio of both anti-spike (anti-S) IgG and neutralizing antibodies (NAbs) between both pediatric age groups to that of adults on day 36. Noninferiority was concluded if the lower bound of 95% CI of this ratio was greater than 0.67 for each age group. Both the antibodies were assessed for the index strain and for selected variants at various time points. Solicited adverse events (AEs) were recorded for 7 days after each vaccination, unsolicited AEs were recorded for 35 days, and serious AEs and AEs of special interest were recorded for 179 days. A total of 460 children in each age cohort were randomized to receive vaccine or placebo. The mean (SD) age was 6.7 (2.7) years in the child cohort and 14.3 (1.6) years in the adolescent cohort; 231 participants (50.2%) in the child cohort and 218 in the adolescent cohort (47.4%) were female. Both anti-S IgG and NAb titers were markedly higher in the SII-NVX-CoV2373 group than in the placebo group on both day 36 and day 180. The geometric mean titer ratios compared to those in adults were 1.20 (95% CI, 1.08-1.34) and 1.52 (95% CI, 1.38-1.67) for anti-S IgG in adolescents and children, respectively; while for NAbs, they were 1.33 (95% CI, 1.17-1.50) and 1.93 (95% CI, 1.70-2.18) in adolescents and children, respectively, indicating noninferiority. SII-NVX-CoV2373 also showed immune responses against variants studied. Injection site reactions, fever, headache, malaise, and fatigue were common solicited AEs. There were no AEs of special interest and no causally related serious AEs. SII-NVX-CoV2373 was safe and well tolerated in children and adolescents in this study. The vaccine was highly immunogenic and may be used in pediatric vaccination against COVID-19. Clinical Trials Registry of India Identifier: CTRI/2021/02/031554.

Full Text